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Introduction
The introduction of anti-tumor necrosis factor (TNF) drugs in our 
daily practice has revolutionized the treatment of several inflamma-
tory diseases, including psoriasis (1, 2). However, up to 30% of pa-
tients treated with these drugs do not respond adequately (primary 
failure) and up to 50% lose response over time (secondary failure) 
(3, 4). Immunogenicity through the induction of anti-drug-antibod-
ies (ADA) is now known to be one of the main causes for this loss of 
response and may also be responsible for safety issues (5). In this 
setting, the evaluation of immunogenicity and drug pharmacoki-
netics has gained importance in recent years and might represent 
the key to using anti-TNF agents in a more economical, cost-effec-
tive way without losing efficacy. The enzyme-linked immunosorb-
ent assay (ELISA) technique has been used to measure both drug 
and anti-drug antibody levels. ELISA is a biochemical assay that 
uses antibodies and an enzyme-mediated color change to detect the 
presence of either antigens (proteins, peptides, hormones, etc.) or 
antibodies in a given sample (6). A sub-type of ELISA—“sandwich” 
ELISA—is a more sensitive method, in which a “capture” antibody 
and a “detection” antibody are utilized, both binding to the pep-
tide one wants to quantitate, but at distinct and non-overlapping 
epitopes, making it a more powerful tool for monitoring immuno-
genicity (7).
Methods
Nineteen patients with psoriasis (with or without psoriatic arthri-
tis) treated with adalimumab were included. The adalimumab 
dosage was the approved dosage for psoriasis (an initial dose of 
80 mg, followed by 40 mg every other week starting 1 week af-
ter the initial dose), except for one patient, who had 2 months of 
double dosage (40 mg/week) after clinical worsening. The serum 
levels of adalimumab and ADAs were measured using the Lisa 
Tracker drug and anti-drug enzyme-linked immunosorbent assay 
(ELISA) kits for Adalimumab (Theradiag®). The samples were col-
lected immediately before the drug administration.
Results
The characteristics of the 19 patients are shown in Table 1. At the 
time of the evaluation, 89% (n = 17) of the patients were respond-
ers (Psoriasis Area Severity Index (PASI) > 75) and 11% (n = 2) were 
partial responders (PASI 50–75). 
The serum levels of adalimumab were lower than the cutoff es-
tablished for the exam in both of the partial responders (PR) and 
the ADA levels were high (Table 2), whereas the other 17 patients 
had adalimumab levels above the cutoff (mean 6.6 µg/ml) and low 
ADA levels (< 10 µg/ml). Figure 1 shows the distribution and rela-
tion between adalimumab and ADA levels. Both PRs were obese 
(body mass index > 35) and none of them were taking methotrex-
ate (MTX). One of the patients had been co-treated with acitretin 
after an initial worsening but had no satisfactory response after 4
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Patient characteristics n = 19
Sex: Female 10 (52.6%)
Age, years (mean ± SD) 56 ± 10
Psoriatic arthritis 12 (63.2%)
Responders (PASI > 75) 17 (89%)
Partial responders (PASI 50–75) 2 (11%)
Duration of treatment w/ adalimumab, months (mean ± SD)
Maximum
Minimum
58 ± 23
83
13
Co-treatment w/ MTX 5 (26.3%)
Table 1 | Patient characteristics. PASI = psoriasis area severity index, MTX = 
methotrexate.
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months, whereas in the other case the dose of adalimumab was 
doubled (40 mg weekly) for 2 months with a slight improvement 
but worsened after returning to the standard regimen. Both pa-
tients were switched to ustekinumab, and a PASI90 response was 
observed after 16 weeks.
Discussion
Immunogenicity is a risk of every treatment based on biological 
drugs, and may lead not only to loss of response but also to de-
velopment of adverse events (5). In this work, the detection of low 
levels of adalimumab and high levels of ADAs using a sandwich 
ELISA correlated with loss of clinical response. The cost of the 
treatment for both patients with partial response might have been 
lower if the measurements had been made earlier. The low num-
ber of patients included and consequently the absence of statisti-
cal significance represent a limitation of this work.
Although there are data regarding immunogenicity of biologi-
cal drugs in psoriasis patients, they are mostly from clinical trials, 
whereas data from real life clinical practice is scant, with reported 
rates of ADA development in adalimumab-treated psoriasis pa-
tients between 6 and 50.9% (8, 9). In a study by Chiu et al., ADAs 
were detected in 50.9% of 53 psoriatic patients treated with adali-
mumab (8). The differences in PASI75 response rates among pa-
tients with and without ADAs were statistically significant (44.4% 
vs. 88.5%; p = 0.001). Patients with ADAs had significantly lower 
trough concentrations of adalimumab than those without ADAs 
(1.27 vs. 3.55 mg/l; p = 0.02). Another study, by Menting et al., 
showed a rate of ADA development of 49% of 80 psoriatic patients 
treated with adalimumab after a period of 52 weeks (9). The pres-
ence of high levels of ADAs correlated with a low adalimumab 
concentration and lack of clinical response. In our study, two pa-
tients (11%) developed ADAs. This rate is lower than the studies 
mentioned; however, the small number of patients and the fact 
that patients had different treatment durations when the meas-
urements were made might justify this difference. One point that 
is in agreement with the previous studies is that the presence of 
high titers of ADAs correlates with low adalimumab concentration 
and a lack of clinical response.
The main risk factors for ADA development seem to be treat-
ment interruption, absence of concomitant methotrexate use, and 
biologics switching (6). In addition, low trough adalimumab lev-
els are associated with and likely secondary to the development 
of ADAs (3).
As for adalimumab serum levels, some studies have aimed to 
define a therapeutic range that corresponds to an optimal clinical 
response. Menting et al. established a therapeutic range of adali-
mumab trough levels of 3.51 mg/l (or µg/ml) to 7.00 mg/l based 
on samples from 135 patients (10). In our study, all patients that 
were responders had serum levels of adalimumab above 3.51 µg/
ml (minimum level 4.6 µg/ml, Figure 1) and both partial respond-
ers had lower levels (Table 2).
These studies are important for establishing protocols for the 
tailored use of these drugs according to each patient, which might 
allow considerable cost savings (10, 11). This is important not only 
in patients that do not respond or lose response to biologics, but 
also in responding patients in which it might be possible to opti-
mize the dose or interval of administration while maintaining ef-
ficacy (11). It will be interesting to use data collected from patients 
with a PASI > 75 and try to optimize the administration of the drug.
Testing immunogenicity and drug pharmacokinetics of biolog-
ical drugs in psoriasis patients will probably be part of the daily 
management of these patients in the near future and should be 
taken into account alongside other factors such as the clinical ef-
ficacy of the drug, the safety profile, and the impact on comorbidi-
ties.
Partial responder characteristics PR 1 PR 2
Age, years 67 46
Sex Male Female
Body mass index 35 39
Psoriatic arthritis No Yes
Co-treatment w/ MTX No No
Duration of treatment w/ adalimumab, months 
Total
w/ partial response*
13 
6
24 
6
Duration of dose optimization, months** 0 2
Adalimumab levels (µg/ml)
Cutoff > 4.9 µg/ml
0.1 0.7
ADA levels (µg/ml)
Cutoff > 10 µg/ml
27.6 9.6
Table 2 | Partial responder (PR) characteristics. MTX = methotrexate, ADA = 
anti-drug antibody.
*From worsening until biologic switch
**Duplication of standard dose regimen
Figure 1 | Distribution of adalimumab and ADA serum levels. Orange dots = 
partial responders (PASI 50–75), blue dots = responders (PASI > 75), ADAs = 
anti-drug antibodies.
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